Medical Nutrition Formulations Enriched with Postbiotics for the Management of Gastrointestinal Disorders
Launched by AB BIOTEK · Dec 13, 2024
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inpatients of the centre
- • Diagnostic of diarrhoea: increase in daily faecal weight \> 200 g (as per the Centre protocol).
- • Subjects who as per the Centre protocol require Oral rehydration therapy
- • Patients with the ability to take the study product orally
- Exclusion Criteria:
- • History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active principle or to any of the excipients.
- • History or evidence of any medical conditions or medication used that, in the opinion of the principal investigator, could affect the safety of the subjects or interfere with the study evaluations
- • Patients in situation of last days
- • Amytriptilin and masalazine treatment (anti-depressives)
- • Laxatives
About Ab Biotek
AB Biotek is a leading biotechnology company specializing in the development and commercialization of innovative bioprocessing solutions for the fermentation and brewing industries. With a strong commitment to advancing microbial technology, AB Biotek leverages cutting-edge research and development to enhance product quality and efficiency for its clients. The company focuses on delivering tailored solutions that optimize yeast performance and fermentation processes, thereby supporting sustainable practices and driving growth in the beverage sector. Through collaborative partnerships and a robust pipeline of clinical trials, AB Biotek aims to set new standards in biotechnological applications and improve overall industry standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported